TW200927158A - A medicament composition capable of lowering blood lipid, anti-high uric acid, and anti-diabetes - Google Patents
A medicament composition capable of lowering blood lipid, anti-high uric acid, and anti-diabetes Download PDFInfo
- Publication number
- TW200927158A TW200927158A TW96148437A TW96148437A TW200927158A TW 200927158 A TW200927158 A TW 200927158A TW 96148437 A TW96148437 A TW 96148437A TW 96148437 A TW96148437 A TW 96148437A TW 200927158 A TW200927158 A TW 200927158A
- Authority
- TW
- Taiwan
- Prior art keywords
- test
- diabetes
- blood fat
- blood
- acid
- Prior art date
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 71
- 239000008280 blood Substances 0.000 title claims abstract description 71
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 42
- 229940116269 uric acid Drugs 0.000 title claims abstract description 22
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 150000002632 lipids Chemical class 0.000 title abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000003178 anti-diabetic effect Effects 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 230000002485 urinary effect Effects 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 240000008415 Lactuca sativa Species 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000007975 buffered saline Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 235000012045 salad Nutrition 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000014101 wine Nutrition 0.000 claims description 2
- 229920002306 Glycocalyx Polymers 0.000 claims 1
- 244000097202 Rathbunia alamosensis Species 0.000 claims 1
- 235000009776 Rathbunia alamosensis Nutrition 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 1
- 210000004517 glycocalyx Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 240000007133 Cordia dichotoma Species 0.000 abstract 4
- 235000005943 Cordia dichotoma Nutrition 0.000 abstract 4
- 238000001035 drying Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 127
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 40
- 241001465754 Metazoa Species 0.000 description 35
- 239000000126 substance Substances 0.000 description 31
- 235000013305 food Nutrition 0.000 description 23
- 235000019197 fats Nutrition 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 18
- 239000004744 fabric Substances 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 235000000346 sugar Nutrition 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 229940088594 vitamin Drugs 0.000 description 13
- 229930003231 vitamin Natural products 0.000 description 13
- 235000013343 vitamin Nutrition 0.000 description 13
- 239000011782 vitamin Substances 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 235000013350 formula milk Nutrition 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- 150000003722 vitamin derivatives Chemical class 0.000 description 9
- 108010023302 HDL Cholesterol Proteins 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 108010028554 LDL Cholesterol Proteins 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000010998 test method Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000699800 Cricetinae Species 0.000 description 6
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 6
- 235000008696 isoflavones Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000000963 osteoblast Anatomy 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 208000032928 Dyslipidaemia Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000019152 folic acid Nutrition 0.000 description 5
- 239000011724 folic acid Substances 0.000 description 5
- 108091005995 glycated hemoglobin Proteins 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 150000002515 isoflavone derivatives Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000002689 soil Substances 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229960000304 folic acid Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 235000019750 Crude protein Nutrition 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 241000282320 Panthera leo Species 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 229930003471 Vitamin B2 Natural products 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- -1 Zinc Iron Vitamin Chemical class 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 235000019164 vitamin B2 Nutrition 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000021049 nutrient content Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000002893 slag Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- GTQXMAIXVFLYKF-UHFFFAOYSA-N thiochrome Chemical compound CC1=NC=C2CN3C(C)=C(CCO)SC3=NC2=N1 GTQXMAIXVFLYKF-UHFFFAOYSA-N 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 240000006063 Averrhoa carambola Species 0.000 description 1
- 235000010082 Averrhoa carambola Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 1
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 102100021023 Gamma-glutamyl hydrolase Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- XCOBLONWWXQEBS-KPKJPENVSA-N N,O-bis(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)O\C(C(F)(F)F)=N\[Si](C)(C)C XCOBLONWWXQEBS-KPKJPENVSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 241000270708 Testudinidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 241000691803 Urobatis jamaicensis Species 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 229940075911 depen Drugs 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229940064302 folacin Drugs 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 108010062699 gamma-Glutamyl Hydrolase Proteins 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 239000009004 jinqing Substances 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000005009 osteogenic cell Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000008265 rhamnosides Chemical class 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 208000001644 thecoma Diseases 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000010389 wendan Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
200927158 九、發明說明: 【發明所屬之技術領域】 本發明係關於一種可降低血脂肪、抗高尿酸及抗糖尿病之醫藥組成 物’特別是指一種含有破布子Forst f.)葉片之水萃取物的 醫樂組成物。 【先前技術】 近年來,由於經濟發展穩定,生活富裕,國人的飲食習慣已由粗茶淡 飯轉變為高油高熱量的精緻美食,再加上生活便利,活動量已不似傳統農 業社會時期來的多,隨之而來的,便是焉血壓、尚血脂症、 糖尿病 '癌症、痛風等文明病。 所§胃馬血脂症’是指血液中的膽固醇(total cholesterol,TC)或三酸甘油脂 (tnacylglycerol,TG)比正常值增加。我國行政院衛生署於1996年訂出國人血 脂異常分類標準,將血脂異常分為三類:高膽固醇血症 (hypercholesterolemia广TC濃度大於200 mg/dL,且高密度脂蛋白膽固酵 (high-density-lipoprctein-cholesterol,HDL-C)的濃度小於 35 mg/dL,或是 TC/HDL-C的濃度比大於5 ;⑵高三酸甘油脂血症(hypertriglyceridemia): TG濃度大於2〇〇 mg/dL ; (3)混合型㈣xedtype): TC及TG濃度均大於2〇〇 mg/dL ° 面血脂症是目前常見的疾病之―’其造成的顧大都是因為脂肪代謝 不正常所致’其好發於中年人身上,主要會引發的常見疾病有動脈粥狀硬 化㈣藝cl_is)以及心血管疾病(嶋卿以如。血脂異常,不論 200927158 疋回膽_血症、向三酸甘油_血症或混合型,都是誘發動脈粥狀硬化的 主因,會增加罹患冠狀動脈心臟病的機^膽_值過高,通常並不會出 現明顯的症狀,报多人常疏忽,血液中_轉如長期過份偏高, 便可此積*在血s內壁上,使這些血管變得狹窄甚至形細塞,而導致心 肌梗塞«頓’·_械院魅查默主要關辑絲(行政院衛 民國94年目人主要死因統計資料,行政院衛生署衛生統計資 訊網。):,罐病、腦血f疾病高居台灣地區娜年主要死亡原目之第二、 二位’而心血賴病為美_歐美先賴家十大死亡原因之首位。一般人 志、黃士ίδ、錢信、揚惠婷、劉職和謝明哲,屬,高膽_飲食添加200927158 IX. DESCRIPTION OF THE INVENTION: TECHNICAL FIELD The present invention relates to a pharmaceutical composition for reducing blood fat, anti-hyperuric acid and anti-diabetes, in particular to a water extract containing a leaf of Forst f. Medical composition. [Prior Art] In recent years, due to stable economic development and affluent life, the dietary habits of Chinese people have changed from coarse tea to high-oil and high-calorie exquisite cuisine. Together with the convenience of life, the amount of activity is no longer the same as in the traditional agricultural society. With it, it is the bloody disease, blood lipids, diabetes, cancer, gout and other civilized diseases. § Stomach horse dyslipidemia refers to an increase in blood cholesterol (TC) or tnacylglycerol (TG) than normal. In 1996, the Department of Health of the Executive Yuan of China set the classification criteria for dyslipidemia in Chinese, and classified dyslipidemia into three categories: hypercholesterolemia (hypercholesterolemia), TC concentration greater than 200 mg/dL, and high-density lipoprotein cholesterol-free yeast (high- The concentration of density-lipoprctein-cholesterol, HDL-C) is less than 35 mg/dL, or the concentration ratio of TC/HDL-C is greater than 5; (2) hypertriglyceridemia: TG concentration is greater than 2〇〇mg/ dL; (3) mixed type (4) xedtype): TC and TG concentrations are greater than 2〇〇mg/dL °. Facial dyslipidemia is a common disease--the cause of Gu Da is due to abnormal fat metabolism. In the middle-aged people, the common diseases that are mainly caused are atherosclerosis (4) art cl_is) and cardiovascular disease (嶋卿如如. dyslipidemia, regardless of 200927158 疋 胆 _ 、 、 、 、 、 、 、 、 、 、 Symptoms or mixed type, are the main cause of atherosclerosis, will increase the risk of coronary heart disease, the gallbladder _ value is too high, usually does not appear obvious symptoms, reported many people often neglect, blood in the turn If the long-term is too high, you can On the inner wall of the blood s, these blood vessels become narrow or even slender, resulting in myocardial infarction «Don'· _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Health Statistics Information Network of the Hospital Health Department.): The disease of canned disease and cerebral blood is the second and second of the main deaths of the Nana in Taiwan. First place. General people, Huang Shi, δ, Qian Xin, Yang Huiting, Liu and Xie Mingzhe, genus, daring _ diet added
的血中總膽固醇應低謂mg/dL,但介於細謂吨胤間的民眾,雖 然不-定需要使㈣物來調控血脂,卻必須嚴格控繼食同時常運動來降 低其濃度,树骑慮_觀紐麻膽_的健紅更為理想(謝孟 紅麴粉末對倉鼠體㈣質代謝之料,巾華民时養學㈣諸,及 243-253。;)。 糖尿病係為種人體新陳代謝障礙的疾病;*於人體内的胰臟不能製 造足夠的絲素’導致㈣糖無法充分進人細胞内,血贿度就會升高形 成糖尿病。糖尿病可分為兩種麵:_為胰島素依賴型糖尿病㈣化 dependent diabetes mellitus,IDDM) ’又稱第—型糖尿病,過去稱為幼年型糖 尿病;由於先天上的體質及後天受翻毒或化學雜等的作職,經由自 體免疫機轉破壞胰島素的β細胞,結果顧無法分泌足_胰島素。而另 i的糖尿病為非騰島素依賴型糖尿病(n〇n_insuiin_depen(jent diabetes 6 200927158 mellitus’NIDDM) ’又稱第二型糖尿病,過去稱為成人型糖尿病;其起因於 先天上的體質,加上後天環境的因素:肥胖、缺少運動、壓力等,導致胰 島素的分料足或魏異常,身财能有效的使職島素,這種情況稱為 (insulin resistance)(Wahab ΝΑ, Weston BS, Roberts T. andThe total cholesterol in the blood should be low as mg/dL, but there is a small amount of money between the people. Although it is not necessary to make (four) substances to regulate blood lipids, it must be strictly controlled and often exercise to reduce its concentration. It is more ideal to ride the _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Diabetes is a disease in which the body's metabolism is impaired; * The pancreas in the human body cannot produce enough silk fibroin', causing (4) sugar not to fully enter the cells, and blood bribes will rise to form diabetes. Diabetes can be divided into two types: _ is insulin-dependent diabetes mellitus (ID), also known as type-type diabetes, formerly known as juvenile-type diabetes; due to congenital constitution and acquired detoxification or chemical miscellaneous At the time of the job, the beta cells of insulin were destroyed by the autoimmune machine, and as a result, the foot_insulin could not be secreted. The other type of diabetes is non-Tengsu-dependent diabetes (n〇n_insuiin_depen (jent diabetes 6 200927158 mellitus 'NIDDM)', also known as type 2 diabetes, formerly known as adult-type diabetes; it is caused by the innate constitution, plus The factors of the environment of the day after tomorrow: obesity, lack of exercise, stress, etc., lead to abnormal insulin or Wei, the body can effectively make the island, this situation is called (insulin resistance) (Wahab ΝΑ, Weston BS, Roberts T. and
Mason R.M., 2002, Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J. Am. Soc. Nephrol. 13: 2437-2445)。 由於糖尿病是-種極為慢性的疾病,其可怕之處在於它可引致多種嚴 重的併發症包減染:紐的併發症簡酸巾毒昏迷最為嚴重,糖尿病多 數發生於治療;f當之病人械染、贿、手麟料間,病人會有疲乏、 軟弱、〇渴、多尿、。惡心等前驅症狀,繼而發生尿少、昏迷、深大呼吸、 呼吸有奇特氣味、血壓下降等餘,這是—_制急症,病者如得不到 適當的治療,昏迷會加深而致死亡。 0 在痛方面’任何人如有糖尿病症狀,且在任何時間血癖值高於200 mg/dL或空腹血醣高於刚mg/dL者,表示有糖尿病;如有糖尿病症狀但血 釀低於以上標準者,應進行耐糖試驗(⑽】咖_ t〇ier_咖,0GTT)。目 • 驗尿病仍無法完全靠藥物來治療,必須靠飲食、運動及藥物三者同時控 =,才可能有效地穩定血糖,以避免或延緩併發症的發生(邮心·,職 'd'lbeT n lyr,C ~ 〇n diabetes C〇mpllCati〇nS and 〇n the diabetes, Clm. Diabetes· 22: 162-198)。 由於服用化學合成的西藥所帶來的副作用及不適,使許多人回過頭來 尋求具有獅、治療這些娜觸傳財轉及本土倾難;其中,破 7 200927158 布子便是一項具有治高血壓、鎮咳、解毒等功能的本土保健植物。 破布子屬於⑽科破布子屬,學名c_w__FOTstf,英文名為 _mingCOTdia’ SebastanPlumC〇rdia,別名破子、樹子仔破果子,為多年 • 生落葉小喬木或小灌木’原產中國廣東、福建、海南島,以及台灣等地, - 分布遍及台灣、中國大陸、菲律賓、馬來西亞、印度、錫蘭及東南亞國家; 台灣則分布於低海拔1000公尺以下至平地。 麵子在#灣早期已錢培,以縣零錢培,分散於田間、山坡及 ® 空地,由於其生命力強、無須制管理以及實用價值,是為台灣古老樹木 1·生果實之’-;I又民間等其果實成熟時採摘,泡在水中洗淨,放在鋼中約 5〜6小B可’待煮熟後榜起’加入鹽水、大蒜、墓等配料,再置於容器中酶潰 約10天即成為佐餐佳餚’風味佳並具有開脾健胃的功效。而根據國立中國 醫藥研究所出版的藥用植物學記載,破布子的藥效分三部份: 1·树皮·主治子宮炎、子宮脫出、久年傷、肺出血、下消; 2.根:可止汗、治高血壓;以及 ® 3_果實:具鎮咳、緩下、解毒、整腸之功效。 在化學組成分上,從破布子中分離到3個生物鹼和n個黃酮及其苷 類’·經鑑定其巾5個黃酮類成分分別為異鼠李黃娜s〇rh_etin)、山奈黃 素(kaempferol)、槲皮黃素(Quercetin)、5,6,4,_三羥基_3,-曱氧基黃酮_7_〇-鼠 ' 李糖基葡萄糖芽(5,6,4,德ydroxyd^methoxyflmmeKX rhamnosylglucoside),以及 5,6,8,4’-四經基黃酮 _7_〇_ 鼠李糖苷 (5,6,8,4’-tetramethoxyflavone-7-0-riiamnoside)。 8 200927158 黃酮類化合物已被證實具有天然抗氧化功能,並可調節免疫力,對於 癌症細胞具有抑制效果;根據林政緯的研究指出(民94,刪促進雖性素 誘導乳癌細胞增生之機轉探討:結構相似類黃崎化合物之活性研究,二 北醫學大學碩士論文)’從二十糖構相似_黃_化合物中,探討不同 結構之間對乳癌細胞增生的抑制情形,實驗結果發現3_〇h黃嗣⑽ηMason R.M., 2002, Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J. Am. Soc. Nephrol. 13: 2437-2445). Because diabetes is an extremely chronic disease, its terrible thing is that it can cause a variety of serious complications including dysplasia: the complications of New Zealand are the most serious coma, and most of the diabetes occurs in treatment; Between dyeing, bribery, and hands, the patient will be tired, weak, thirsty, and polyuria. Nausea and other prodromal symptoms, followed by oliguria, coma, deep breathing, breathing with a strange smell, blood pressure drop, etc., this is - _ emergency, if the patient does not receive proper treatment, the coma will deepen and die . 0 In terms of pain, 'anyone who has diabetes symptoms and has a blood stasis value higher than 200 mg/dL or fasting blood glucose higher than just mg/dL at any time indicates diabetes; if there is diabetes, but the blood is lower than the above The standard should be tested for sugar tolerance ((10)] coffee _t〇ier_cafe, 0GTT).目 • The urinalysis still cannot be completely treated by drugs. It must be controlled by diet, exercise and drugs at the same time. It is possible to effectively stabilize blood sugar to avoid or delay the occurrence of complications (Zhou Xin·, job 'd' lbeT n lyr, C ~ 〇n diabetes C〇mpllCati〇nS and 〇n the diabetes, Clm. Diabetes 22: 162-198). Due to the side effects and discomfort caused by the use of chemically synthesized western medicine, many people have turned back to seek to have lions, to treat these sensational traits, and to turn to the locals. Among them, the broken 7 200927158 cloth is a cure for hypertension. Local health care plants with functions such as antitussive and detoxification. The rag is belonging to the genus (10) genus, the scientific name is c_w__FOTstf, the English name is _mingCOTdia' SebastanPlumC〇rdia, the alias is broken, the tree is broken, and the fruit is for many years. The deciduous small tree or small shrub is native to Guangdong, Fujian, Hainan, China. The island, as well as Taiwan and other places, - distributed throughout Taiwan, China, the Philippines, Malaysia, India, Ceylon and Southeast Asian countries; Taiwan is distributed below the low altitude of 1000 meters to the flat. Faced in the early days of #湾, Qianpei, with the county's change, spread over the fields, hillsides and ® vacant land. Because of its vitality, unmanageable management and practical value, it is the fruit of Taiwan's ancient trees. When the fruit is ripe, the fruit is picked, soaked in water and washed, placed in steel about 5~6 small B. 'When cooked, list it', add salt, garlic, tomb and other ingredients, and then put it in the container. In 10 days, it becomes a good meal with a good flavor and has the effect of spleen and stomach. According to the medicinal botany published by the National Institute of Chinese Medicine, the efficacy of the rags is divided into three parts: 1. Bark · Indications for uterine inflammation, uterus prolapse, long-term injury, pulmonary hemorrhage, and elimination; Root: can stop sweat, cure high blood pressure; and ® 3_ fruit: with antitussive, slowing down, detoxification, and intestinal function. In the chemical composition, three alkaloids and n flavonoids and their glycosides were separated from the rags. · The five flavonoids of the towel were identified as isoflavone s〇rh_etin and kaempferol. ), quercetin (Quercetin), 5,6,4,_trihydroxy-3,-nonoxylated flavonoids _7_〇-mouse' plumose glucose bud (5,6,4, de ydroxyd^methoxyflmmeKX rhamnosylglucoside ), and 5,6,8,4'-tetramyl flavonoid _7_〇_rhamnoside (5,6,8,4'-tetramethoxyflavone-7-0-riiamnoside). 8 200927158 Flavonoids have been shown to have natural antioxidant functions, and can regulate immunity, which has inhibitory effects on cancer cells; according to Lin Zhengwei's research (Min 94, deletion promotion, although the induction of breast cancer cell proliferation by sex is discussed: Study on the activity of the structurally similar class of Huangqi compounds, Master's thesis of Erbei Medical University) 'Investigate the inhibition of breast cancer cell proliferation between different structures from the similarity of the twenty-sugar composition_yellow compound. The experimental results found that 3_〇h Huang Wei (10) η
肠㈣、岭师aempfe蛛料畴、料她滅m)以及樹 皮黃素(querce㈣能有效阻斷人類乳癌細胞株mcf_7中雄性細姨島素生 長因子(E2/鹏)所誘導脱和⑽蛋白質表現,進而抑制細胞增生和惡性 轉型;而郭保辰則在其研究中指出(民92,人類肺癌細胞中·Μη蛋白的 表達與雛:-氧缝供給者無翻奴侧,歸大㈣士論文),當 分別處理槲皮黃素(q臓etin) _〇福)24小時後,隨著濃度增加會降低 肺癌細胞存醇與健細胞壯,同時抑制細魅長和增加G施時期細 胞。 此外,黃嗣類化合物具有清除自由基、抵抗自由基對細胞的傷害,以 及防止心血管疾病等功效;高料在其研究中指出(民%,異黃酮素對糖尿 病血管平滑肌細胞增生及移行機制之探討:综論,輔仁大學碩士論文), 70-80%的成人糖尿病患死於糖尿病併發症一粥狀動脈硬化,而血管平滑肌細 胞的增纽移行是離動脈硬化發展重要因子,崎平滑餘胞的増生則 是受到血小魅長目子及⑽素_發,_ Mitogen aetiyity prctein (MAPK)路徑可向上調節血小板生長因子及内皮素;而異黃酮素是自然界中 存在的酷胺酸受器抑制劑,研究顯示,異黃酮素可抑制路握的進行, 9 200927158 對於糖尿病心血管疾病患者,異細素可能可以藉由抑制峨傳導路徑來 抑制血小板生制子及内皮素所引起的血t平滑肌細朗增生及移行,因 而下降罹病率及致死率。 更進-步地,黃嶋化合物亦已碰實可有奴善女性更年期症狀, 預防骨質疏鬆;根據吳克威的研究顯示(民國92,探討異黃_素對造骨細胞 與姓骨細胞之生長、分化及生理活性之影響,高雄醫學大學硕士論幻,三 種異黃崎㈣細η或daidzem、bl〇ch_ A或三種異黃嗣素併用 之藥物濃度下,均可促進造骨細胞之前趨細胞之增生並分化城熟的造骨 細胞,並促進成熟造骨細胞之骨生成作用;而三種異黃酮素於MM之寧 «度下,均可抑織骨細胞之前趨細胞的生長與分化成熟,以及抑制成 触骨細胞之骨再錢另外,_化侧職效益之影響分析試驗 中之結不,三種異黃鲷素於1〇-6 M之藥物濃度下,均可促進造骨細胞 礦化結即W,財卩則他__歧之實驗組的 ❹ 促進效果尤其顯著;而於異黃_造骨細胞之前趨細胞之細胞移行影響 貫驗結果可知,三„黃_於1q.6 M讀物濃度下,只有三種異黃國素 用下才有明顯促進造骨細胞之前趨細胞之細胞移行的趨性;由此研 =果證實,異黃明素能促進造骨細胞增生及成熟並抑制韻骨細胞之生成 來達到調節骨質代謝之作用。 張肇宇、李佩端(民國77,破布子降血糖作用及化學成分 辦院料論文)自破布子根部侧之化學成分包括 p sitosterol > 生物絲'堂 _ ’且可明顯降低大白鼠的血糖與Α脂肪;而黃文琪的 200927158 研究指出,(民國69,破布子敝之成份分析及其對子宮職細胞毒性作用 之研究,國立台灣大學碩士論文),在細胞培養的研究中亦證實破布子樹皮 確實可抑制癌細胞之生長;此外,蕭慧美等人則採取破布子葉片的水及甲 醇萃取液’分別和人類肝癌細胞株(HepG2)進行培養,發現兩種萃取液在高 濃度下(0_1 mg/mL甲醇萃取液和〇·5 mg/mL水萃取液)皆明顯降低肝癌細胞 株(HepG2)的細胞存活率。 ❺ 另根據美國腿允許食品中含有黃豆重要成分得標示“有益心血管健 康”’異黃酮素能有效降低血液中低密度膽固醇(LDL),提升高密度膽固醇 (HDL)已是不爭的事實;由此可見,含有大量黃綱類成分的破布子亦具有治 療心血管疾病及其他相關疾病的應用潛力。 在實際制上’輯㈣榮先生於實用臺群討科巾所揭露破布子 的服用方法,在治療尿酸部份,分域服方及後服方兩部份,在^服方部 份:需先將生破布子納人土雞腹内,加水職,喝湯吃肉,連服h日Intestinal (4), Lingshi aempfe spider material domain, expected to destroy m) and bark flavin (querce (4) can effectively block the male cellulite growth factor (E2/Peng) induced by human breast cancer cell line mcf_7 (10) protein expression Inhibition of cell proliferation and malignant transformation; and Guo Baochen pointed out in his research (Min 92, the expression of Μη protein in human lung cancer cells and chicks: - the oxygen seam supplier has no nucleus side, Guida (four) scholar paper), When treated with quercetin (q臓etin) _ 〇 )) for 24 hours, the concentration of lung cancer cells decreased with the increase of concentration, and the cell growth and cell growth were inhibited. In addition, xanthine compounds have the effect of scavenging free radicals, resisting free radical damage to cells, and preventing cardiovascular diseases; high materials indicate in their research (Min%, isoflavones on the proliferation and migration mechanism of diabetic vascular smooth muscle cells) : Comprehensive review, Fu Jen University master's thesis), 70-80% of adults with diabetes die from diabetes complications - atherosclerosis, and the migration of vascular smooth muscle cells is an important factor in the development of arteriosclerosis, smoothing the residual cells The twins are regulated by the blood-stained scorpion and (10) _ _, _ Mitogen aetiyity prctein (MAPK) pathway can upregulate platelet growth factor and endothelin; and isoflavones are naturally occurring urethane receptor inhibitors, research It is shown that isoflavones can inhibit the conduct of the road grip, 9 200927158 For patients with diabetic cardiovascular disease, isozyme may inhibit the smooth proliferation and migration of blood t smooth muscle caused by platelet biosynthesis and endothelin by inhibiting the sputum conduction pathway. , thus reducing the rate of morbidity and mortality. Further, step by step, Astragalus compounds have also been found to have menopausal women's menopausal symptoms, prevent osteoporosis; according to Wu Kewei's research (Republic of China 92, to explore the growth of osteoblasts and bone cells of the same name, The influence of differentiation and physiological activity, Kaohsiung Medical University master's illusion, three kinds of different huangqiqi (four) fine η or daidzem, bl〇ch_ A or three isoflavin combined drug concentration, can promote the proliferation of osteoblasts before the cells and Differentiate the mature osteoblasts and promote the osteogenic effect of mature osteoblasts; and the three isoflavones can inhibit the growth and differentiation of the pre-existing cells and inhibit the formation of the susceptor. In addition, the three kinds of isoflavin can promote the osteogenic cell mineralization at the drug concentration of 1〇-6 M. The effect of 实验 他 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Three different yellow countries The following is the tendency to promote cell migration of osteoblasts before the cells; this study confirmed that isoflavin can promote osteoblast proliferation and maturation and inhibit the formation of rhythm cells to achieve the role of regulating bone metabolism. Zhang Yuyu, Li Pei Duan (Republic of China 77, Broken Cloth Hypoglycemic Effect and Chemical Composition) The chemical composition of the root side of the broken cloth includes p sitosterol > Bio Silk 'tang_' and can significantly reduce blood sugar and sputum in rats. Fat; and Huang Wenqi's 200927158 study pointed out that (Republic of China 69, analysis of the composition of rags and its cytotoxicity on the uterus, National Taiwan University Master's thesis), in the cell culture study also confirmed that the rags bark indeed Inhibition of the growth of cancer cells; in addition, Xiao Huimei et al. used water and methanol extracts of rags leaves to culture human hepatoma cell lines (HepG2), respectively, and found that the two extracts were at high concentrations (0_1 mg/mL methanol). Both the extract and the 〇·5 mg/mL water extract significantly reduced the cell viability of the liver cancer cell line (HepG2). Xu food contains important ingredients of soybeans labeled "beneficial cardiovascular health" 'Isoflavones can effectively lower low-density cholesterol (LDL) in the blood, and it is an indisputable fact to increase high-density cholesterol (HDL); thus, it can be seen that it contains a large number of The rags of the composition also have the potential to be used in the treatment of cardiovascular diseases and other related diseases. In the actual system, Mr. Rong (Mr. Rong) in the practical Taiwan group to discuss the method of taking the rags, in the treatment of uric acid, The domain service party and the post-service party are in the service part: you need to first put the broken cloth in the belly of the chicken, add water, drink soup and eat meat, and even serve h
之後在使職服方,後服方為:將破布子樹根與土雞肉—起燉爛,〜喝L 肉,服至録為止。另外,錯錢術雜,物布子樹根、拘: 根、白緒母乳、臭茉莉根、玉米鬚—起煎煮,水 ^ z〜’渣以水5碗 烈1碗’兩次煎湯合併,分三次飯各服一次 破;^_Μ ΜΙ 的部份’則需 破布子一層皮、白粗糠、珍珠草、三消草、 服恥化根、白馬齒莧一起前 …、,水8碗煎3碗,去渣後加豬痩肉燉爛,分三次服用。 ‘、、、 另外,徐順裕先生在救人青草藥㈢中,則揭 另種使用破布子來 4糖尿病的配方:將破布子皮、薯榔乾 、辨月起燉煮後服用。而在 11 200927158 破布子葉片的彻上’則極少被世人所提到,僅知破布子葉對於急性腎炎 具有療效。 由此可見1知伽破布子來降錄及級的方法,配方複雜、步驟 繁複,且多伽破布子陳及樹皮,由於取腿物陳及齡都會對該植 株生長造_壞’再加上縣來由於淡食及素食的興起,綺魏破布子 的價值,及重新對它的·和定位,帶動絲伽破布子的軸,食用的 人愈來愈多,帶域培面積逐年增加,產品價格也就居高不下丨因此,若 能研發翻破布子植株中最取、也最不會影響其生長的料部分,來 達到抗高血壓、高尿酸及糖尿病的效果,將使破布子的應用更具產業價值, 成本可大崎低’將可造福更多為高血壓敎明病所苦的民眾。 由此可見,上述習用利用破布子植株來治療高血壓、高尿酸及糖尿病 的配方仍有諸多缺失,實非―良善之設計者,而雜加以改良。 本案發明人祕上述制破布子植株來治療高血壓、高尿酸及糖 尿病的配謂触的各·點,乃亟思加贿_新,並經多年苦心職 潛心研究後,終於成功研發完成本件—種可降低錢肪、降高尿酸及抗糖 尿病之醫樂組成物。 【發明内容】 單之可降低血脂 本發明之目的即紐提供—種材《取得、製程簡 肪'抗高尿酸及抗糖尿病之醫藥組成物。 本如月之次-目的係在於提供一種成本低廉、療效好之可降低血脂 肪、抗高尿酸及抗糖尿病之醫藥組成物。 12 200927158 可達成上紐㈣之—種可$低 曰肪抗南尿酸及抗糖尿病之醫 樂,、且成物’係包含破布子㈣取物及藥學上可接受之載劑。 …該破布子葉片萃取物細適#_的水做為溶劑,於—適當溫度下進 =咕破布蝴細嫩__至η嶋百分比骨 卒取/皿度可為30〇:至121t,萃取時間為%分鐘到μ小時,紐分離得 到破布子葉片萃取液。 ❹After the service, the latter is: the rags roots and the chicken are simmered, ~ drink L meat, served until the record. In addition, the wrong money, miscellaneous, cloth cloth roots, arrest: root, Bai Xu breast milk, stinky jasmine root, corn must - boil, water ^ z ~ 'slag with water 5 bowls of 1 bowl of 'two decoction combined Divide three times for each meal; the part of ^_Μ ' needs to break the fabric with a layer of skin, white rough, pearl grass, three grass, shame root, white horse teeth together..., water 8 bowls Fry 3 bowls, add the pork chop meat to the slag, and take it in three times. ‘,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, And on 11 200927158, the rags of the rags are rarely mentioned by the world, only the rags are effective for acute nephritis. This shows that the method of knowing the gambling of the rags and descending the record is complicated, the steps are complicated, and the gamma-breaking cloth and the bark are caused by the growth of the leg and the age of the plant. Due to the rise of light food and vegetarian food, the value of Wei Wei breaking the cloth, and repositioning it, and driving the axis of silk rags, more and more people are eating, the area of the area is increasing year by year, and the price of the product is also increasing. Therefore, if you can develop the most suitable and least affected parts of the cloth plant to achieve antihypertensive, high uric acid and diabetes, it will make the application of rags more The industrial value, the cost can be high and low, 'will benefit more people suffering from high blood pressure and disease. It can be seen that there are still many shortcomings in the above-mentioned formula for treating high blood pressure, high uric acid and diabetes by using a rag plant, which is not a designer of goodness, but is improved. The inventor of this case secretly made the above-mentioned rags plant to treat high blood pressure, high uric acid and diabetes, and it was a new one. After many years of painstaking research, he finally succeeded in research and development. A medical composition that can reduce the body weight, reduce uric acid and prevent diabetes. SUMMARY OF THE INVENTION The purpose of the present invention is to reduce blood lipids. The purpose of the present invention is to provide a pharmaceutical composition for obtaining high-uric acid and anti-diabetes. This is the second month of the month - the purpose is to provide a pharmaceutical composition that is low in cost and effective in reducing blood fat, anti-hyperuric acid and anti-diabetes. 12 200927158 Achieving the New Zealand (4)--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...the dapped leaf extract is fine as the solvent, at the appropriate temperature, the 咕 布 蝴 蝴 _ __ to η 嶋 percentage bones / dish can be 30 〇: to 121t, extraction The time is from % minutes to μ hours, and the detached leaves extract is obtained. ❹
该破布子葉片萃取液可直接作為本發明之可降低血脂肪 、抗高尿酸及 抗糖尿病之醫藥組成物,或配合藥學上可接受之載劑,如:稀釋劑、賦形 劑或載體’以製成各種形式之製劑,如:錠劑、膠囊、顆粒劑、溶液劑、 糖聚劑等;此外’該破布子封萃取液亦可進—步進行濃縮或乾燥,再配 合藥學上可接受之_,以f成各獅式之製劑。 5亥稀釋劑可為極性溶劑,如:水、醇類、酮類、酯類或其組合,較佳 者為水、醇、水/醇混合物、生理食鹽水、缓衝水溶液、缓衝食鹽水等。 該賦形劑或載體可為液體或固體形式,如:乳糖、糊精、澱粉、玉米 殺粉、硬脂酸納等’液體賦形劑或載體包括:水、沙拉油、酒、果汁等。 【實施方式】 實施例一破布子葉片萃取物之萃取以及膠囊之製備 將120 kg破布子葉片以清水洗淨後,浸於2000 L水中,於1〇〇。(:萃取 8小時’然後過濾分離得到破布子葉片萃取液。 將所得到之破布子葉片萃取液濃縮至3.1 Kg後’混合適當比例之賦型 劑(玉米澱粉),並以喷霧造粒機製成粉末,再混合硬脂酸鎂,並以膠囊機充 13 200927158 填製成破布子葉片萃取物膠囊。 實施例二破布子葉片成分分析 取破布子葉片萃取物膠囊進行成分分析,成分分析結果如表—所示, 結果顯示破布子萃取物具有五大營養素··蛋白質、醣類、脂質、維生素及礦 物質,且其礦物質钾含量高達5290 PPm,顯*破布子葉片具有利尿之作用。 表一破布子葉片萃取物成分分析結果 ❹ 檢今g目 檢驗結果 單位 檢驗方法 熱量The detached leaf extract can be directly used as a pharmaceutical composition for reducing blood fat, anti-hyperuric acid and anti-diabetes of the present invention, or with a pharmaceutically acceptable carrier such as a diluent, an excipient or a carrier. Formulated into various forms, such as: tablets, capsules, granules, solutions, sugar-polymerizing agents, etc.; in addition, the rag-packed extract can be further concentrated or dried, and then combined with pharmaceutically acceptable _, to f into each lion-type preparation. 5H diluent can be a polar solvent, such as: water, alcohols, ketones, esters or a combination thereof, preferably water, alcohol, water / alcohol mixture, physiological saline, buffered aqueous solution, buffered saline Wait. The excipient or carrier may be in liquid or solid form, such as: lactose, dextrin, starch, corn flour, sodium stearate, etc. The liquid excipient or carrier includes water, salad oil, wine, fruit juice and the like. [Embodiment] Example 1 Extraction of the leaf extract of the rags and preparation of the capsules The 120 kg rag leaves were washed with water and immersed in 2000 L of water at 1 Torr. (: 8 hours of extraction) and then separated by filtration to obtain the extract of the burr leaf. After concentrating the obtained burr leaf extract to 3.1 Kg, 'mix the appropriate proportion of the excipient (corn starch) and spray granulator The powder is prepared, and magnesium stearate is mixed, and filled into a rag fabric leaf extract capsule by a capsule filling machine 13 200927158. Example 2 Fragment analysis of the rag fabric leaves The component of the detached cloth leaf extract capsule is analyzed, and the component analysis result is obtained. As shown in the table, the results show that the rag extract has five major nutrients · protein, sugar, lipids, vitamins and minerals, and its mineral potassium content is as high as 5290 PPm, which shows that the leaves of the rags have diuretic effect. A broken cloth leaf extract composition analysis results 检 check g-test results unit test method heat
ND(MDL=2) 5290 ppm 以感應偶合電將光譜儀 (ICP/OES)分析 以感應偶合電將光譜儀 (ICP/OES)分析 以感應偶合電將光譜儀 (ICP/OES)分析 鈣 5270 ppm ND (MDL=2) ppm 以感應偶合電將光譜儀 銅it 龜 4.50 ppm (ICP/OES)分析 以感應偶合電將光譜儀 (ICP/OES)分析 13.2 ppm 以感應偶合電將光譜儀 (ICP/OES)分析 ND (MDL=2) ppm 磷 以感應偶合電將光譜儀 (ICP/OES)分析 664 ppm 以感應偶合電將光譜儀 (ICP/OES)分析 鎂 553 ppm 以感應偶合電將光譜儀 (ICP/OES)分析 鎘 ND (MDL=2) ppm 以感應偶合電將光譜儀 (ICP/OES)分析 14 200927158 ΟND(MDL=2) 5290 ppm Analytical Coupled Spectrometer (ICP/OES) for Inductively Coupled Spectrometer (ICP/OES) Analysis to Inductively Coupled Spectrometer (ICP/OES) Analysis of Calcium 5270 ppm ND (MDL =2) ppm Analytical coupling of copper spectrometer copper tortoise 4.50 ppm (ICP/OES) for inductive coupling. Spectrometer (ICP/OES) analysis of 13.2 ppm for inductive coupling. Spectrometer (ICP/OES) analysis of ND (MDL) =2) ppm Phosphorus Inductively Coupled Spectrometer (ICP/OES) Analyze 664 ppm to Inductively Coupled Spectrometer (ICP/OES) Analyze Magnesium 553 ppm to Inductively Coupled Spectrometer (ICP/OES) Analyze Cadmium ND (MDL) =2) ppm Analyze the spectrometer (ICP/OES) by inductively coupled electricity 14 200927158 Ο
檢驗項目 檢驗結果 單位 檢驗方法 鐵 45.1 ppm 以感應偶合電將光譜儀 (ICP/OES)分拚 硫 518 ppm 以感應偶合電將光譜儀 (ICP/OES)分柑 蛾 ND (MDL=2) PPm 以感應偶合電將光譜儀 (ICP/OES)分柄 維生素A ND (MDL-3) ppm 備註 維生素C 16.2 ppm 備註 維生素D 62.93 mg/lOOg 備註 胡蘿蔔素 66.3 ppm 備註 葉酸 0.29 ppm 備註 維生素氏 0.4 PPm 備註 維生素b2 6.5 ppm 備註 維生素b6 ND (MDL=1) ppm 備註 膳食纖維 10.36 % 備註 維生素Ε-α 33.7 PPm 備註 維生素Ε-/3 9.21 ppm 備註 維生素Ε-γ 11.1 ppm 備註 維生素Ε-δ 11.4 ppm —---- 備註 於驗酸 16.7 ppm 備註 有機酸(草酸) 0.06 g/l〇〇g 備註 氯 ND :低於方法偵測極 (MDL)。 25.97 限之測定值以「ND」 mg/lOOg 表示,並於檢驗結果相 備註 -_1 3 δ主明其方法偵測極限 備註: 水分 胁白i 豕標準cns 5Q33臓4,1984食品中水份之檢驗方法」。 m中國國家標準cns 5〇35 N6u6,1986「食品中粗蛋白質之檢驗方土 匕CNS 3449N6065, 1988「乳品檢驗法-蛋白質之定量不贫曰貨之檢驗方法J及 粗脂肪·參考中國國家標準CNS 5〇36 N6n7,1984「 灰份:參考中國國家標準CNS5〇34N6ii5,觸口 :如月曰肪之檢驗方法」。 碳水化,物:依行政院衛生署「台灣地區食品營 份之檢驗方法」。 扣除其中之水分、粗蛋白質、粗月旨肪及灰分等含量計Ϊ」100g可食部分樣品 15 200927158 熱量··依行政院衛生署「台灣地區食品營養成分資料庫」,依樣本100g中粗蛋白質、 脂肪及碳水化合物之含量分別乘以其個別知熱量係數4、9、4而得。 ' 鈉:參考中國國家標準CNS 12869 N6231,1991 r嬰兒配方食品中礦物質之檢驗方法-銅、 鐵、錢、猛、_、納、辞之檢驗」。 維生素A : 1.行政院經濟部標準檢驗局,1990,嬰兒配方食品中維生素a含量測定法。 2.CNS 8859 n6168,1982。 , 維生素 Bi (Vitamin B!): 1. AOAC, 1984, Thiamine (Vitamin B〇 in Grain products Fluorometric (Rapid) Method Final Action, pp. 837=838. 2. Analytical procedures for the Determination of vitamins in Multivitamin preparations, Fluorimetric Determination of vitamin Bi (Thiochrome Method pp 35-36, ROCHE). 維生素 B2 (Vitamin B2) . Analytical procedures for the Determination of vitamins inInspection item test result unit test method iron 45.1 ppm Inductive coupling electric spectrometer (ICP/OES) is divided into sulfur 518 ppm to induce coupling electric spectrometer (ICP/OES) to divide citrus moth ND (MDL=2) PPm to induce coupling Electric spectrometer (ICP/OES) split vitamin A ND (MDL-3) ppm Remarks Vitamin C 16.2 ppm Remarks Vitamin D 62.93 mg/lOOg Remarks Carotene 66.3 ppm Remarks Folic acid 0.29 ppm Remarks Vitamin 0.4 PPm Remarks Vitamin b2 6.5 ppm Remarks Vitamin b6 ND (MDL=1) ppm Remarks Dietary fiber 10.36 % Remarks Vitamin Ε-α 33.7 PPm Remarks Vitamin Ε-/3 9.21 ppm Remarks Vitamin Ε-γ 11.1 ppm Remarks Vitamin Ε-δ 11.4 ppm —---- Remarks Acid test 16.7 ppm Remarks Organic acid (oxalic acid) 0.06 g/l〇〇g Remarks Chlorine ND: Below the method detection electrode (MDL). The measured value of the limit of 25.97 is expressed as "ND" mg/lOOg, and the test result is remarked -_1 3 δ Mainly its method detection limit Remarks: Water threat white i 豕 standard cns 5Q33臓4, 1984 food moisture Testing method". m China National Standard cns 5〇35 N6u6, 1986 "Inspection of crude protein in foods CNS 3449N6065, 1988 "Determination of dairy products - Quantitative analysis of protein non-poor goods J and crude fat · Reference Chinese national standard CNS 5〇36 N6n7, 1984 “Grey: refer to the Chinese national standard CNS5〇34N6ii5, contact: such as the test method of the month.” Carbonization, substances: According to the “Inspection Method for Food Camps in Taiwan” by the Department of Health of the Executive Yuan. Deducting the content of water, crude protein, crude fat and ash, etc." 100g edible portion sample 15 200927158 Heat · According to the "Taiwan Regional Food Nutrition Database" of the Department of Health of the Executive Yuan, according to the sample of 100g of crude protein The fat and carbohydrate content are multiplied by their individual known caloric coefficients of 4, 9, and 4. 'Sodium: Refer to China's national standard CNS 12869 N6231, 1991 r. Test methods for minerals in infant formulas - copper, iron, money, fierce, _, nano, resignation test." Vitamin A: 1. Standards Inspection Bureau of the Ministry of Economic Affairs of the Executive Yuan, 1990, Determination of vitamin A in infant formula. 2. CNS 8859 n6168, 1982. Vitamin B (Vitamin B!): 1. AOAC, 1984, Thiamine (Vitamin B〇in Grain products Fluorometric (Rapid) Method Final Action, pp. 837=838. 2. Analytical procedures for the Determination of vitamins in Multivitamin preparations, Fluorimetric Determination of vitamin Bi (Thiochrome Method pp 35-36, ROCHE). Vitamin B2 (Vitamin B2) . Analytical procedures for the Determination of vitamins in
Multivitamin preparations, Fluorimetric Determination of vitamin B2, pp. 39-40 ROCHE. ’ ' 維生素 B6 : USP 21 版 ρ· 276. ASSAY FOR Pyridoxine Hydrochloride。 維生素C :小高要、道節子、氏家隆、上野頤士、須田耗行,1985,維生素c之定量, 維他命59451-457曰本東京昭和電工株式會社。 維生素 E : Speek,A.J·,J. Schrijver and W.H.P. Schreurs,1985, “Vitamin E Determination of some Sedd Oils as Determined by High Performance Liquid Chromatography withMultivitamin preparations, Fluorimetric Determination of vitamin B2, pp. 39-40 ROCHE. ’ 'Vitamin B6: USP version 21 ρ· 276. ASSAY FOR Pyridoxine Hydrochloride. Vitamin C: Xiaogao, Daozizi, Shijialong, Ueno Gentleman, Suda consumption, 1985, Quantification of vitamin C, Vitamin 59451-457 曰本日本昭昭电工股份有限公司. Vitamin E: Speek, A.J., J. Schrijver and W.H.P. Schreurs, 1985, “Vitamin E Determination of some Sedd Oils as Determined by High Performance Liquid Chromatography with
Fluorometric Detection”,J. of Food Sci·,Vol. 50, pp· 121-124. 維生素 D: Detemiined by Folch,et al. (1956) fat extraction method, NaOH saponification and BSTFA dericatization and GC-MS determination. 沒-胡蘿蔔素:Journal of Food Protection, Vol· 56, NO. 1 Page 51-54 (January 1993) Quantification of Provitammin A Compounds in Chinese Vegetables by High-Performance Liquid Chromatography. 終驗酸(Niacin) : AO AC, 1984, Niacin and Niacinamide in Drugs, Foods, and Feeds colorimetric Method pp. 841-842. 葉酸:依據 a. AOAC,1990, Folic acid (Pteroylglutamic acid) in Vitamin Preparations, Microbiological Methods, Sec. 944, 12,1082-1083. b. Kirsch, A. J. and Chen T.S. (1984) Comparison of conjugase treatment procedures in the microbiological assay of food folacin. J. Food. Sci. 49: 94-98. c. Ball, GF.M. (1994). Water-soluble vitamin assays in human nutrition, pp. 351-355. 草酸、氣:委託財團法人食品工業發展研究所試驗測得。 破布子葉片萃取物與其他常見食物的營養成分含量如表二所示;與這 些常見蔬果及食物比較,破布子葉片萃取物的營養含量明顯比這些食物高 出許多倍,如表三所示;以礦物質鉀含量為例,破布子葉片萃取物的鉀含 16 200927158 里為辣木的2倍、文旦的4 8倍、柳丁的4.4倍、檸檬的44倍、葡萄抽的 8.1 L葡萄的4.4倍、西瓜的5 3倍、琶樂的3 5倍、楊桃的5·29倍草 €的2.9倍;顯示破布子葉片萃取物具有豐富的營養成分。 ❹ φ 表二成分含量表 (單位:毫克)Fluorometric Detection", J. of Food Sci., Vol. 50, pp. 121-124. Vitamin D: Detemiined by Folch, et al. (1956) fat extraction method, NaOH saponification and BSTFA dericatization and GC-MS determination. -Carotene: Journal of Food Protection, Vol. 56, NO. 1 Page 51-54 (January 1993) Quantification of Provitammin A Compounds in Chinese Vegetables by High-Performance Liquid Chromatography. Final Acid (Niacin): AO AC, 1984 , Niacin and Niacinamide in Drugs, Foods, and Feeds colorimetric Method pp. 841-842. Folic acid: according to a. AOAC, 1990, Folic acid (Pteroylglutamic acid) in Vitamin Preparations, Microbiological Methods, Sec. 944, 12,1082-1083 b. Kirsch, AJ and Chen TS (1984) Comparison of conjugase treatment procedures in the microbiological assay of food folacin. J. Food. Sci. 49: 94-98. c. Ball, GF.M. (1994). Water -soluble vitamin assays in human nutrition, pp. 351-355. Oxalic acid, gas: commissioned by the Food Industry Development Research Institute of the consortium. The nutrient content of the food and other common foods is shown in Table 2; compared with these common fruits and vegetables and food, the nutrient content of the leaf extract of the rags is significantly higher than that of these foods, as shown in Table 3; For example, the potassium content of the extract of the burr leaf is 16 times that of sapwood in 200927158, 48 times of Wendan, 4.4 times of lycopene, 44 times of lemon, 4.4 times of 8.1 L of grape, and watermelon. 5 3 times, 3 5 times of the music, and 2.9 times of the 5.29 times of the carambola; the leaf extract of the rag is rich in nutrients. ❹ φ Table 2 ingredient content table (unit: mg)
葉片萃取物營養成分為其他食物之倍數對照表 表三破布子Leaf extract nutrient composition is a comparison table of other foods. Table 3 Broken cloth
(單位:倍數) 鋅 鐵 維生 素Β2 膳食 纖維 13 132 45.1 32.5 10.36 17 200927158(Unit: multiple) Zinc Iron Vitamin Β 2 Dietary fiber 13 132 45.1 32.5 10.36 17 200927158
將貫施例—所制之破布子料萃取物提供給具有糖尿病之試驗者服 用。酬4 _天)後,抽取受測者後技液,_物食後血 >T,t «m^t^CGluoose fasting) ; ; 〇外其禁食後i液中葡萄糖濃度為攻mg/dL ;而賴驗*週後,其禁食 後血液中葡雜濃度為135 mg/dL,顯示本發贿提供之可降低血脂肪、抗 高尿酸及抗糖尿病之醫藥組成物,確實具有降低血糖的作用。 實施例四調節血糖功能試驗_動物試驗 1.試驗材料及試驗方法 本試驗係參照行政院衛生署公告之「健康食品之調節血糖功能評估方 法」規範執行試驗’以Wistar大白鼠為試驗動物,並以菸鹼胺(Nicotinamide) 及鏈脲佐菌素(Streptozotocin,STZ)誘發高血糖(非胰島素依賴型(第二型)糖 18 200927158 尿病動物);待誘發成功後,每日給予實施例一所得到之破布子葉片萃取物 (即試驗物質)持續8週;經由觀察空腹錄值、葡雜雜、糖化血色素 (HbAlc)或其他-般生化分析等項目’並將各數據以spss生物統計檢定軟 體中Owy ANOVA類數分^Dunean,s喊如㈣卿_檢定法進 行試驗組與控制組之差異性比較’以評估試驗物妓否具有調節錄之效 果。 U試驗動物及飼養環境: 1-1.1試驗動物:Wistar大白鼠 1丄2動物來源:國立台灣大學醫學院實驗動物中心 1.1.3動物性別:雄鼠 1.1.4飼養條件: a.溫度:22 土 2 0C b·相對溼度:55 ±5% c·光照:12小時之光暗週期(〇7:〇〇〜19:〇〇) d·飼養狀況:2隻1籠 U.5飲水:自由供飲 I·2第二型糖尿病的誘導: 將8週大的大鼠先禁食15·24小時,再分別稱過體重後,每隻均以腹腔 /射的方式給予200 mg/kg的聽胺(s聊a c。,概),過15分鐘後,再主 =她輪繼_ ; 蝴導期後, 木測里空事24小時)血糖值,若超㈣球時則視為誘發成功, 19 200927158 即可開始投予試驗物質。The rag aggregate extract prepared by the example was supplied to a tester having diabetes. After paying 4 _ days), after taking the test subject's technical solution, _ after eating blood > T, t «m^t^CGluoose fasting);; after the fasting, the glucose concentration in the liquid is attacking mg/dL After the test, the blood concentration in the blood after the fasting was 135 mg/dL, indicating that the drug composition provided by the bribe can reduce blood fat, anti-hyperuric acid and anti-diabetes, and indeed has blood sugar lowering. effect. Example 4: Adjusting Blood Glucose Function Test _ Animal Test 1. Test Materials and Test Methods This test is based on the "Test Method for Evaluating Blood Glucose Function of Healthy Foods" published by the Department of Health of the Executive Yuan, using Wistar rats as test animals, and Hyperglycemia was induced by Nicotinamide and Streptozotocin (STZ) (non-insulin-dependent (type 2) sugar 18 200927158 urinary animal); after successful induction, Example 1 was administered daily. The obtained burr leaf extract (ie, test substance) was continued for 8 weeks; by observing items such as fasting recording, glutamate, glycosylated hemoglobin (HbAlc) or other biochemical analysis, and each data was verified by spss biostatistics. The number of Owy ANOVA in the software ^Dunean, s shouted as (four) Qing _ test method to compare the difference between the test group and the control group 'to assess whether the test substance has the effect of adjustment record. U test animals and breeding environment: 1-1.1 Test animals: Wistar rats 1丄2 Animal source: National Taiwan University School of Medicine Experimental Animal Center 1.1.3 Animal Sex: Male 1.1.4 Feeding conditions: a. Temperature: 22 soil 2 0C b · Relative humidity: 55 ± 5% c · Illumination: 12 hours of light and dark cycle (〇7: 〇〇~19: 〇〇) d· Feeding conditions: 2 cages U.5 Drinking water: free to drink I.2 Induction of Type 2 Diabetes: Eight-week-old rats were fasted for 15·24 hours, and then weighed separately, each of which was given 200 mg/kg of the amine by abdominal cavity/shot ( s chat ac., general), after 15 minutes, then the main = her succession _; after the butterfly period, the wooden test in the air for 24 hours) blood sugar value, if the super (four) ball is considered to induce success, 19 200927158 The test substance can be started to be administered.
鼠每公斤體重之攝取劑量=人體建議攝取量署所魏公式進行換算 例’則大鼠劑量為〇.1〇4 g/kg。 贱置(60kg) X 6.25。以每人每日服用The dose per kilogram of body weight of the rat = the recommended dosage of the human body is calculated by the Department of Health's formula. The rat dose is 〇.1〇4 g/kg. Set (60kg) X 6.25. Take per person per day
1·4動物觀察、測試項目及方法: 1A1臨床症狀觀察:試驗期間每日進行臨床觀察,並記錄動物是否有異 吊£^床症狀或死亡。 ⑷動_重:畴週及触t日量顺記軸物體重。 1A3飼料消耗量:於試驗期間每週定。 I·4.4樣本收集及處理:齡8週後犧牲動物,動物犧牲前禁食⑽小 時,犧牲採集其血液,並進行分析。 1.5糖化血色素檢測分析: 糖化血色素是峰評傭尿献鼠8 _域控繼狀監控指標。 將血液檢體注人含乙燁二胺四乙酸_Α抗凝▲劑,如❿”似)的收 集試管後,以高效能液騎析法(HPLC ; BiG_RadVariantll)進行測定。 1.6血糖測定: 使用拜耳公司(Bayer)出產之AscensiaTM凡^#2/ CONFIRM/ Glucometer®瓜血糖測定儀。在採血後,利用毛細管作 20 200927158 用把血液樣核進試條内;錢樣本__難試條的葡雜氧化酶鐵 氰化鉀發魏學反應,產生㈣錄紐本⑽㈣糖濃度成正比。 1.7 葡萄糖耐性試驗(oral glucose tolerance test,OGTT). 試驗開始前,大鼠絲食15·24小時。麵量"分賴錄值後,給 予大鼠0.5 g/kg葡萄糖,之後取大鼠尾巴血液分_量給糖後第%、6〇、 120及180分鐘的血糖值變化。 <1 Φ 2.試驗結果 2.1 §式驗物質對體重、攝取量的影響: 表四結果顯示在飼養的8週期間,控制組動物的補每日攝取量為45 〇 土 〇·8 g,試驗組的飼料每日攝取量為44·3地g,各組之間的攝取量彼此並 無顯著差異(p>aG5);且兩組間動物體重與體重減少量也無差躲>〇〇5)。 驗物質8週,體重與攝取量之變化量 ~ ' -----—- . —_____________ —熏(g)結束體重(g)體重減少⑻ 控制組 45.〇-^^7 " 241.8,9.9 _5式驗組 44.3 i 〇,8 980 δ 〇- 1 >i ^ ** 註:所S7數據皆以 --3 234.5 ± 18.9 55.3 ±6.9 2.2试驗物質對糖化灰色素的影響. 由表五之<4驗、纟。果顯不經過8週的飼養期後,試驗組的糖化血色素為 6 4.2%與控制組的糖化血色素口3 土㈣相比較皆無顯著差異^ > 0·05) 〇 21 200927158 響 表五大白鼠餵食不同濃度驗物質8週後,對糖化血色素之影 組別 動物編號1-4 Animal observation, test items and methods: 1A1 clinical symptom observation: daily clinical observation during the test, and record whether the animal has different symptoms or death. (4) Dynamic _ heavy: The domain circumference and the amount of t-days are recorded in the weight of the shaft. 1A3 feed consumption: fixed weekly during the test period. I·4.4 Sample collection and treatment: After 8 weeks of age, the animals were sacrificed. The animals were fasted (10) hours before sacrifice, and their blood was sacrificed and analyzed. 1.5 Glycated hemoglobin detection and analysis: Glycated hemoglobin is the peak evaluation of the urinary hamster 8 _ domain control succession monitoring indicators. The blood sample is injected into a collection tube containing acetaminophentetraacetic acid Α anti-coagulant ▲ agent, such as ❿ 似, and then measured by high-performance liquid riding method (HPLC; BiG_RadVariantll). 1.6 Blood glucose measurement: use Bayer's AscensiaTM Fan^#2/ CONFIRM/ Glucometer® Melon Blood Glucose Analyzer. After blood collection, use the capillary tube for 20 200927158 to use the blood sample to enter the test strip; the money sample __ difficult test strip of Portuguese The heterogeneous oxidase potassium ferricyanide reacts with Wei, and produces (4) New Zealand (10) (4) the concentration of sugar is proportional. 1.7 Glucose tolerance test (OGTT). Before the start of the experiment, the rat silk food for 15 24 hours. After the amount is recorded, the rats are given 0.5 g/kg glucose, and then the blood content of the tail of the rat is given to change the blood glucose levels at the first, sixth, 120 and 180 minutes after the sugar. <1 Φ 2 Test results 2.1 § Effect of test substance on body weight and intake: The results in Table 4 show that during the 8 weeks of feeding, the daily intake of the control group was 45 〇 〇 · 8 g, and the test group's feed per The daily intake is 44·3 g, and the intake between each group is mutual There was no significant difference (p>aG5); and there was no difference in animal body weight and body weight loss between the two groups. 〇〇5). After 8 weeks of examination, the change in body weight and intake amount ~ ' ----- - . -_____________ - smoked (g) end weight (g) weight loss (8) control group 45. 〇-^^7 " 241.8, 9.9 _5 type test group 44.3 i 〇, 8 980 δ 〇 - 1 > i ^ * * Note: The S7 data are all -3 234.5 ± 18.9 55.3 ±6.9 2.2 The effect of the test substance on the glycated gray pigment. According to the test of Table 5, <4, the fruit is not after 8 weeks of feeding period. The glycated hemoglobin in the experimental group was 6 4.2% and there was no significant difference compared with the glycated hemoglobin 3 soil (4) in the control group ^ > 0·05) 〇21 200927158 The five white rats were fed with different concentrations of substances for 8 weeks, and the glycated hemoglobin Shadow group animal number
II --------—-—J-- HbAlc (%) 控制組 17.6 12.6II --------—-—J-- HbAlc (%) Control Group 17.6 12.6
IIIIII
IVIV
Mean ± SD 變化率(%) a --------- 15.9 11.4 23.2 11.3 17.3 ±2.2 17.6 ± 4.2 18.3 29.3 11 -試驗 2.3試驗物質對空腹血糖值的影響: +1.4 表六結果顯示在飼養的第4、6及8週分別測量試驗動物的空腹血糖 值’攝取試驗物質8週之祕其空腹錄絲絕職值上與控制組相比有 下降之趨勢’試驗組下降3 8%,但在統計上並無顯著差異〇 〇5)。Mean ± SD rate of change (%) a --------- 15.9 11.4 23.2 11.3 17.3 ±2.2 17.6 ± 4.2 18.3 29.3 11 - Test 2.3 Effect of test substance on fasting blood glucose values: +1.4 Table 6 results are shown in At the 4th, 6th and 8th week of feeding, the fasting blood glucose level of the test animals was measured. 'The ingestion of the test substance for 8 weeks was the same as that of the control group. The test group decreased by 3 8%. However, there is no statistically significant difference 〇〇5).
❹❹
白鼠不同濃度勿質8週後,對空腹血糖值之影響 動物編號/ mg/dL π ΠΙ iv Mean ±SD 變化率(〇/0); ❹ 234 292 295 234 402 400 305 311 309.0 士 34.7 309.3 ± 34.4 +1.4 284 394 374 338 400 396 388.5 ± 5.9 337 399 367·0 ± 17· 1 -5.5 434 330 449 399 403.0 ±26.5 •2.9 386 389 377 414 391.5 ±7.9 391 392 362Effects of fasting blood glucose levels on white rats at different concentrations for 8 weeks. Animal number / mg/dL π ΠΙ iv Mean ±SD rate of change (〇/0); ❹ 234 292 295 234 402 400 305 311 309.0 ± 34.7 309.3 ± 34.4 +1.4 284 394 374 338 400 396 388.5 ± 5.9 337 399 367·0 ± 17· 1 -5.5 434 330 449 399 403.0 ±26.5 •2.9 386 389 377 414 391.5 ±7.9 391 392 362
363 346 377.0 ± 8.4 362.8 ±7.8 -3.8 22 200927158 2.4試驗物質對耐糖試驗的影響: 在8週的飼養期中,於第4、6及8週分別測量試驗動物的雜情形, 試驗組與㈣組之間在血輕化的断上均錢著差抑 > ⑽)(㈣广再 進:步計算錄上升曲線下之面積,攝取試驗物質的動物在第4、6及8週, 其葡萄糖上升曲線下面積與控制組相比分別下降了 8.1%、2.3%及1〇 6%。 3.總結: ❹ 本試驗結果顯示Wi伽大鼠每日攝取〇. 15 g/kg之試驗物f m 所仔到之破布子葉片萃取物)持續8週後,對於驗胺及鏈服佐菌素(卿誘導 出之第二型(非絲雜_)糖尿病从,在线血概和着試驗中有下 降之趨勢,顯示在本試驗條件下之破布子葉片萃取物具有部份調節血糖之 - 能力。 實施例五降低尿酸功能試驗_人體試驗 將實施例-所得到之破布子葉片萃取物提供給二位具有尿酸過高之試 驗者(試驗者A、B)服用。經服用4週(28天)後,檢驗受測者A、B之尿液 樣本,以測量其尿液中尿酸濃度(uricacid);結果如表七所示,受測者A在 試驗進行前(試驗第〇天),其尿液中尿酸濃度為13吨胤,經試驗4週後, 、K液中尿g文》辰度為7.9 mg/dL,而受測者B在試驗進行前(試驗第〇天), 其尿液中尿酸濃度為7.8 mg/dL,經試驗4週後,其尿液中尿酸濃度為63 mg/dL ;顯示本發明所提供之可降低血脂肪、抗高尿酸及抗糖尿病之醫藥組 成物’確實具有降低尿酸的作用。 23 200927158 表七破布子葉片萃取物降低尿酸試驗之結果 尿酸濃度(mg/dL)363 346 377.0 ± 8.4 362.8 ±7.8 -3.8 22 200927158 2.4 Effect of test substances on sugar tolerance test: In the 8 week feeding period, the test animals were measured at 4, 6 and 8 weeks, respectively, and the test group and (4) group (10)) (4) Wide re-entry: The area under the rising curve is recorded, and the glucose uptake curve is observed at 4, 6 and 8 weeks for the animals ingesting the test substance. The area under the lower than the control group decreased by 8.1%, 2.3% and 1.6% respectively. 3. Summary: ❹ The results of this test showed that the daily intake of 伽. 15 g/kg of test rats fm After 8 weeks of burr leaf extract, there was a downward trend in the online blood test and the test for the test of the amine and the chain of sputum (the second type (non-filament) induced by Qing. The burlap leaf extract shown under the conditions of this test has a partial blood sugar-regulating ability. Example 5: Reducing uric acid function test _ human test The example - obtained rag fabric leaf extract is provided to two persons with uric acid High testers (testers A, B) take 4 weeks (28 days) The urine samples of the test subjects A and B were tested to measure the uric acid concentration in the urine; the results are shown in Table 7. The test subjects A before the test (test day), the urine The concentration of uric acid was 13 tons 胤. After 4 weeks of testing, the urinary g of the K solution was 7.9 mg/dL, while the subject B was in the urine before the test (test day). The concentration of uric acid was 7.8 mg/dL. After 4 weeks of testing, the concentration of uric acid in the urine was 63 mg/dL. It shows that the pharmaceutical composition of the present invention which can reduce blood fat, anti-hyperuric acid and anti-diabetes does have Reduce the effect of uric acid. 23 200927158 Table 7 Broth-leaf leaf extracts reduce the result of uric acid test uric acid concentration (mg / dL)
試驗者A 試驗者B 試驗前(試驗第0天)試驗後(試驗第28天) 13 7.8 7.9 6.3 ❹Tester A Tester B Before the test (day 0 of the test) After the test (day 28 of the test) 13 7.8 7.9 6.3 ❹
總膽固醇 前(試驗第0天)試驗後(試驗第28夭、 318 186Total cholesterol before (test day 0) test (tests 28th, 318 186)
試驗材料及試驗方法 實施例六降低血脂肪功能試驗-人體試驗 將實施例一所得到之破布子葉片萃取物提供給具有高血壓之試驗者服 用。由於過高的總膽固醇及三酸甘油醋(triglyceride)皆是,罹患冠狀動脈心臟 病、中風、高血壓等心血管疾病的重要危險因子;因此,受測者經服用本 發明之醫藥組成物4週(28天)後’抽取受測者禁食後之血液,並測量其企 液中總膽’及三酸甘油酯的濃度,以評估本發明之醫藥組成物抗高血壓 之效果;結果如表八所示,受測者在試驗進行前(試驗第〇天),其血液中總 膽固醇及三酸甘油_濃度分別為318 mg/dL及·呵胤;而經試驗4 後’其血液中總膽固醇及三酸甘油g旨的濃度分別為186 mg/dL及綱 mg/dL ’顯示本發明所提供之可降低血脂肪、抗高尿酸及抗糖尿病之醫藥組 成物,確實具有降低高血壓危險因子及抗高血壓的作用。 表八破布子葉片萃取物降低尿酸試驗之結果 血脂肪濃度(mg/dL) 24 200927158 本試驗係參照行政院衛生署公告之「健康食品之調節血脂功能評估方 法」規範執行類:。以倉鼠作職㈣為試驗動物,並以冑顏飼料誘發動物 血清脂值’鋼_實_-所得狀破布子料萃轉(即物質)混合 入娜中顧食6週後,抽血測其血脂,並將各數據以〇ne_way an〇va進行 、.先"十刀析如出現有顯著差異,再以Duncan,s mu〗tiple_range纪对進行組間 差異性之比較’·娜其血雜麵改變來評估試驗物具有調節血脂 之效果。 1.1試驗動物及飼養環境: 1.1.1試驗動物:Syrian hamster (敘利亞倉鼠) 1.12動物來源:財團法人國家實驗研究院國家實驗動物中心 1 · 1.3試驗動物品系選擇理由:倉鼠在肝臟脂質代謝方面作用與人體最為 相符’並且為衛生署公告「職食品之調節錢舰評估方法」規 範中建議採用之實驗動物。 、 1.1.4動物性別:雄鼠 1丄5飼養條件:Test Materials and Test Methods Example 6 Test for lowering blood fat function - human test The shredded leaf extract obtained in Example 1 was supplied to a tester having hypertension. Because of the high total cholesterol and triglyceride, it is an important risk factor for cardiovascular diseases such as coronary heart disease, stroke, and hypertension. Therefore, the subject is administered the pharmaceutical composition of the present invention. After the week (28 days), the blood of the test subject was fasted, and the concentration of total gallbladder ' and triglyceride in the liquid solution was measured to evaluate the antihypertensive effect of the pharmaceutical composition of the present invention; As shown in Table 8, the subjects' blood total cholesterol and triglyceride concentration were 318 mg/dL and 胤 前 before the test (the first day of the test), and the blood was tested after the test 4 The concentrations of total cholesterol and triglyceride are 186 mg/dL and mg/dL, respectively. The pharmaceutical composition of the present invention for lowering blood fat, anti-hyperuric acid and anti-diabetes has the potential to reduce the risk of hypertension. Factors and the role of antihypertensive. Table 8: Results of uric acid test by burlap leaf extracts Blood fat concentration (mg/dL) 24 200927158 This test is based on the “Evaluation method for regulating blood lipid function of healthy foods” published by the Department of Health of the Executive Yuan. The hamsters were employed as the test animals, and the serum lipid value of the animal induced by the 胄 饲料 饲料 ' 钢 钢 钢 钢 钢 所得 所得 所得 所得 所得 所得 所得 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 Blood lipids, and the data are carried out by 〇ne_way an〇va. First, there is a significant difference in the appearance of the ten-knife, and then Duncan, s mu〗tiple_range is used to compare the differences between the groups. The face change was used to evaluate the effect of the test article on regulating blood lipids. 1.1 Test animals and breeding environment: 1.1.1 Test animals: Syrian hamster (Syrian hamster) 1.12 Animal source: National Experimental Animal Center of the National Experimental Research Institute of the Foundation 1 · 1.3 Test animal strain selection Reasons: The role of hamsters in liver lipid metabolism The human body is the most consistent' and is the experimental animal recommended in the specification of the Department of Health's "Evaluation Method for Adjusting the Money of the Foods". 1.1.4 Animal sex: Male 1丄5 Feeding conditions:
a. 溫度:22 ± 2 〇C b. 相對溼度:55 ±5% c·光照:12小時之光暗週期(〇7:〇〇〜19:〇〇) d·飼養狀況:2隻1籠 U.6飼料··控制組即試驗組(含〇.3%試驗物質)飼料組成與配製如表九所 示’採自由攝取方式餵食。以細_93M為基礎飼料配方進行修飾, 25 200927158 將趣修改為1G%大豆油及添加α2%膽畴以提供動物必需脂肪 '、'敗實驗動物產生⑥血腊,所增〜之油脂從其原施-遍 飼料中玉米殿粉的百分比中扣除。 表九各組飼料成分表a. Temperature: 22 ± 2 〇C b. Relative humidity: 55 ± 5% c · Illumination: 12 hours of light and dark cycle (〇7: 〇〇~19: 〇〇) d· Feeding status: 2 1 cage U .6 Feed··Control group ie the test group (containing 〇.3% test substance) The feed composition and preparation are as shown in Table IX. Modified with a fine _93M based feed formula, 25 200927158 modified the taste to 1G% soybean oil and added α2% biliary domain to provide animal essential fat ', 'the experimental animal produces 6 blood wax, the added fat from the Deducted from the percentage of corn house powder in the original application-through feed. Table 9 Table of feed ingredients
飼料成分 組別 ---—-—_ 試驗物質 控制組 --*----- 試驗組 0.30 Cornstarch 40.369 40.08 Dextrinized Cornstarch 15.5 15.5 Casein 14.0 13.992 Sucrose 10.0 10.0 Soybean oil 10.0 9.997 Alphacel, non-nutritive bulk 5.0 5.0 AIN-93M-MX 3.5 3.5 AIN-93M-VX 1.0 1.0 ’ Choline bitartrate 0.25 0.25 L-Cystine 0.18 0.18 Tert-Butylhydroquinone 0.001 0.001 Cholesterol 0.2 0.2 Total 100.0 ~—--- 100.0 1.飼料配方基於ΑΙΝ-93Μ,使用於嚅齒類實驗動物(Reeves, 1997)。 1.1.7飲水:自由供飲。 1.2試驗物質劑量與試驗組別: 試驗組別 飼料種類a 餵食物質 劑量(%) ' ~~_ 隻數 控制組 高油脂飼料 — — _ 4 試驗組 高油脂飼料 試驗物質 0.3b ~—--- 26 200927158 a :以AI^3^基礎谢斗配方進行修飾,將油脂修改為1〇%大豆油 成為咼油,飲&,以誘發試驗動物產生高血脂。所增加之油脂 , 中預=粉的百分比中扣除。試驗經6週,犧牲動物進行各項分^斤原觀93Μ飼料 b:劑量^士·以成人每曰攝食乾重500 g計算,以每人每曰建議攝取 作為基準’?該產品佔每日食品之攝取量的。獅的χ 1〇〇% = 〇.3%。太 混加0.3%之試驗物質,而按其組成分別取代控制組飼料中之玉米殿粉。"將飼料 動物觀察、測試項目及方法: 1.3.1臨床症狀觀察:試驗期間每日進行臨床觀察,並記錄動物是否有異 常床症狀或死亡。 1.3.2動物秤重.於试驗期間每週及犧牲當日量測並記錄動物體重。 ΟFeed ingredient group------_ test substance control group------- test group 0.30 Cornstarch 40.369 40.08 Dextrinized Cornstarch 15.5 15.5 Casein 14.0 13.992 Sucrose 10.0 10.0 Soybean oil 10.0 9.997 Alphacel, non-nutritive bulk 5.0 5.0 AIN-93M-MX 3.5 3.5 AIN-93M-VX 1.0 1.0 ' Choline bitartrate 0.25 0.25 L-Cystine 0.18 0.18 Tert-Butylhydroquinone 0.001 0.001 Cholesterol 0.2 0.2 Total 100.0 ~—--- 100.0 1. The feed formula is based on ΑΙΝ-93Μ, Used in caries experimental animals (Reeves, 1997). 1.1.7 Drinking water: Free to drink. 1.2 Test substance dose and test group: Test group feed type a Feed food quality dose (%) ' ~~_ Only control group high fat feed --_ 4 Test group high fat feed test substance 0.3b ~---- 26 200927158 a : Modified with AI^3^ basic thank-you formula, the fat was modified to 1〇% soybean oil to become oyster sauce, drink & to induce high blood lipids in the test animals. The added fat, deducted from the percentage of pre-powder. After 6 weeks of experiment, sacrifice animals to carry out various points. The original amount of 93 Μ feed b: dose ^ 士 · calculated by the adult per serving dry weight 500 g, with the recommended intake per person as the benchmark '? The amount of food intake. The lion's χ 1〇〇% = 〇.3%. 0.3% of the test substance was added too much, and the corn house powder in the control group feed was replaced by its composition. "Feed Animal Observation, Test Items and Methods: 1.3.1 Clinical Symptom Observation: Clinical observations were made daily during the trial and animals were recorded for abnormal bed symptoms or death. 1.3.2 Animal Weighing. Animal weight was measured and recorded weekly and on the day of sacrifice during the trial. Ο
1.3.3飼料消耗量:於試驗期間每週定時記錄飼料消耗量。 1.3.4樣本收集及處理.餵食6週後犧牲動物,動物犧牲前禁食i2_i6小 時。犧牲採集其血液,並進行分析。 1.3.5血脂檢測分析: a.血清三酸甘油醋(serum triacylglycerol,TG): 使用測定血清三酸甘油酯之試劑組(購自RANDOXLaboratories Ltd·),其利用酵素呈色法進行測定,原理如下(K〇ditschek&Umbrd, 1969):三酸甘油脂經脂酶(iipase)水解後的產物過氧化氳毋2〇2),再 經過氧化酶(peroxidase)的催化作用,與4-aminophenazone及 4-chlorophenol反應,而產生紫紅色的职—加化合物,再使用 ELISAreader在波長500nm下測得吸光值,最後再以標準品之吸光 值換算血清三酸甘油酯濃度,其公式如下: 檢體濃度(mg/dL)=1.3.3 Feed consumption: The feed consumption was recorded periodically during the test period. 1.3.4 Sample collection and treatment. After 6 weeks of feeding, the animals were sacrificed and the animals were fasted for i2_i6 hours before sacrifice. Sacrifice to collect blood and analyze it. 1.3.5 Analysis of blood lipids: a. Serum triacylglycerol (TG): A reagent group for measuring serum triglyceride (purchased from RANDOX Laboratories Ltd.) was used, which was determined by the enzyme coloring method. The principle is as follows: (K〇ditschek & Umbrd, 1969): The product of triglyceride hydrolysis by lipolysis (iipase), ruthenium peroxide 2〇2), followed by catalysis by oxidase (peroxidase), with 4-aminophenazone and 4 -chlorophenol reaction, which produces a purple-red occupational-addition compound, and then uses an ELISA reader to measure the absorbance at a wavelength of 500 nm. Finally, the concentration of the serum triglyceride is converted by the absorbance of the standard. The formula is as follows: Mg/dL)=
Standard OD - Blank OD Sample OD - Blank OD 標準品濃度(mg/dL) 27 200927158 b.血清總膽固醇(serum total cholesterol,TC): 使用測定血清總膽固醇之試劑組(購自RANDOX Laboratories Ltd·) ’利用酵素呈色法進行測定,原理如下Ch()lesteiOl Educational Program Expert Panel, 1988):血清總膽固醇經酵素水解 及氧化作用後的產物過氧化風(H2〇2) ’再經過氧化酶(peroxidase)的 催化作用,與4-aminophenazone及4-chlorophenol反應,而產生紫 紅色的quioneimine化合物,再使用ELISA reader在波長500 nm下Standard OD - Blank OD Sample OD - Blank OD Standard Concentration (mg/dL) 27 200927158 b. serum total cholesterol (TC): a reagent group (purchased from RANDOX Laboratories Ltd.) using serum total cholesterol The enzyme coloring method is used for the following principle. Ch()lesteiOl Educational Program Expert Panel, 1988): Peroxidase (H2〇2), a product of serum total cholesterol hydrolyzed and oxidized by enzymes, and then subjected to peroxidase. Catalytic reaction with 4-aminophenazone and 4-chlorophenol to produce a purplish red quioneimine compound, using an ELISA reader at a wavelength of 500 nm
測得吸光值,最後由標準品之吸光值換算總膽固醇濃度,其公式如 下: 檢體濃度(mg/dL)=The absorbance is measured, and finally the total cholesterol concentration is converted from the absorbance of the standard. The formula is as follows: Sample concentration (mg/dL) =
Standard OD - Blank OD Sample OD - Blank OD x標準品濃度(mg/dL) c•血清面禮度脂蛋白膽固醇(serum high-density-lipoprotein-cholesterol, HDL-C) · 利用酵素作用及比色測定之原理,先取定量的血清加入適當的 沉殿劑’將chylomicrons、VLDL及LDL沉殿,作用完全之後將其 離心,取定量上清液並加入測定膽固醇之試劑,在波長5〇〇nm下測 定吸光值’與標準品比對’經計算後可得HDL_c的濃度。 d·金清低禮、度脂蛋白膽固醇(serum i〇w_density-lipoprotein- cholesterol,LDL-C): 利用酵素作用及比色測定之原理,取定量之血清加入適當的沉 殿劑將LDL沉澱,作用完全之後將其離心,取定量上清液並加入測 28 200927158 定膽固醇之試劑,在波長 nm下測其吸光值,與標準品比對,經 計算後,翻總咖驗扣紅清_轉值,即可得的濃 2.試驗結果: 2.1 §式驗物質對體重、攝取量的影響: 表十結果顯示,在飼養的6週躺內,控制組動物的飼㈣日攝取量 Ο W.7 土 0_4 g ’而試驗組的飼料每日攝取量為5·5 ± g 4 §,兩組之間的攝取 餘統計上彼此並無顯著差齡〉⑼5);而且各組_物體重與體重增加 量等都沒有統計的差異(p>〇 〇5)。 表十倉鼠飯食(試驗組)/不银食(㈣組)試驗物質6週,對體重與攝取量之Standard OD - Blank OD Sample OD - Blank OD x standard concentration (mg/dL) c• serum high-density-lipoprotein-cholesterol (HDL-C) · Determination of enzyme action and colorimetry The principle is to first take a quantitative amount of serum and add the appropriate sinking agent. The chylomicrons, VLDL and LDL are immersed in the temple. After the action is completed, the centrifugation is performed, and the quantitative supernatant is taken and added to the reagent for measuring cholesterol, and the wavelength is determined at a wavelength of 5 〇〇 nm. The absorbance value 'Compared with the standard' is calculated to obtain the concentration of HDL_c. d·serum i〇w_density-lipoprotein-cholesterol (LDL-C): Using the principle of enzyme action and colorimetric determination, a certain amount of serum is added to the appropriate sinking agent to precipitate LDL. After the action is completed, centrifuge it, take the quantitative supernatant and add the reagent for measuring cholesterol in 200927158. Measure the absorbance at the wavelength nm, compare it with the standard product, and after calculation, turn the total coffee to check the red clear _ turn Value, the available concentration 2. Test results: 2.1 § The effect of the test substance on body weight, intake: Table 10 results show that in the 6 weeks of feeding, the control group of animals (4) daily intake Ο W. 7 soil 0_4 g 'and the daily intake of the test group was 5·5 ± g 4 §, the intake difference between the two groups was statistically not significantly different from each other> (9) 5); and each group _ body weight and weight There is no statistical difference in the amount of increase, etc. (p>〇〇5). Table 10 hamster meals (test group) / no silver food (group 4) test substance for 6 weeks, for body weight and intake
變化量Amount of change
:所有數據皆以Mean 士 SE表示(n=4) b : 巧進行修狀高油脂飼料。以成人每曰攝食乾重 之播攝取置L5 g武驗物質作為基準,則該產品佔每日食品 ^攝取里的(1·5/500)χ 100/〇 = 0.3%。因此本試驗是將試驗組飼料混加〇 3%之試驗物 貝0 2.2試驗物質對血清脂質的影響: 由表十一之試驗結果顯示,經過6週的飼養期後,試驗組的血清三酸 甘油脂(TG)濃度為146.7 ± 6.4 mg/dL ’與控制組的血清三酸甘油脂(TG)濃度 158.7 ± 16·2 mg/dL相比較’在絕對數值下降7.6%,但在統計上並無顯著差 異(p〉〇_〇5)。 29 200927158 表十一倉鼠餒食試驗物質6週後,對血清生化值之影響 動物編號 I II ΙΠ IV Mean ± SD 變化率(%)b TG (mg/dL)c -- ^ . 丨〜 控制組 134.4 167.4 165.8 167.2 158.7 i 16 2 試驗組 141.5 154.5 141.3 149.4 146.7±6 4 -7.6 TC (mg/dL) 1— — 控制組 317.3 371.2 306.8 319.2 328.6 i 28.9 試驗紐· 299.0 310.6 298.1 334.6 310.3 i 17 〇 -5.5 LDL-C (mg/dL) —1 - 控制組 133.6 143.6 121.5 136.1 133.7 ±9.2 試驗組 125.5 112.5 121.0 125.7 121·2±26Π -9.4 HDL-C (mg/dL) —- 控制組 131.8 68.2 102.3 162.8 116.3 ±40.5 試驗組 114.7 82.2 82.2 51.26 -29.0 LDL-C/HDL-C ----- 控制組 1.0 2.1 1.2 0.8 1.3 :b〇.6 試驗組 1.1 1.4 1.5 2.5 1-6 i n a +23.1 500 g計算,以每人每日建議攝取量1.5 g試驗物質作為準食, J攝取频W) X臟=0.3%。叫試驗是賴驗組 b :變化率=(控制組-試驗組)/控制組X 100%。 ❹ ❹ C月旨膽甘油脂;TC :總膽瞒;LDL_C :健麟蛋蝴_ ; HDLC :高密度 由表十-之試驗結果顯示經過6週的飼養期後,試驗組的血清總膽固 醇(TC)濃度S 310.6± 17.〇mg/dL,與控制、组金清總膽固醇(TC)濃度328.6 士 28.9 mg/dL比权後’雖有5·5%的下降情形,但在統計上並無顯著差異^ > 30 200927158 0.05)。 由表十一之試驗數據顯示試驗組的血清低密度脂蛋白膽固醇(LDL-C) 為121.2 ± 6.2 mg/dL ’和控制組的133.7 土 9·2 mg/dL比較,雖有9.4%的下 降情形,但在統計上並無顯著差異(p > 〇.〇5);而血清高密度脂蛋白膽固醇 (HDL-C)濃度則在試驗組及控制組分別為82.6 士 26.0和116.3 ± 40.5 mg/dL ’經統計後結果顯示並無顯著差異⑦> 0 05)。 在控制組和試驗組中進一步計算產生動脈粥狀硬化危險因子指標 LDL-C /HDL-C比例,分別為1.3 ± 0.6與1.6 土 0.6,但在統計上並無顯著差 異b>0.05) 〇 3.總結: 本試驗結果顯示倉鼠每日攝取含0·3%之試驗物質(即實施例—所得到 之破布子葉片萃取物)持續6週時俱有些微降低血清中三酸甘油脂(TG)、總 膽固醇(TC)及低密度脂蛋白膽固醇(LDL-C)的情形,分別下降7.6、5_5及 9.4% ’但在增加血清中高密度脂蛋白膽固上則無明顯差異;因 此,在本試驗條件下之破布子葉片萃取物具有部份調節血中脂質之能力。 本發明所提供之一種可降低血脂肪、抗高尿酸及抗糖尿病之醫藥組成 物’與刚述習用配方相互比較時,更具有下列之優點: 1.本發明所提供之可降低血脂肪、抗高尿酸及抗糖尿病之醫藥組成物 係以破布子葉片為材料,因此不會像根及樹皮―樣取材後_木生長有破 壞性的影響,且取材較根及樹皮鮮,亦可節省人工,所以可大幅降低材 料的成本。 31 200927158 2·本發明所提供之可降低血脂肪、抗高尿酸及抗糖尿病之醫藥組成物 製程to早’且不需搭配其他藥方即可具有部份調節灰脂、尿酸及血糖之功 效,因此具有發展成為抗高血壓、高尿酸及糖尿病之科學巾藥之潛力。 - i顺細_係針縣發明之—可行實齡彳之频制,惟該實施例 • 並非㈣關本發明之專利範®,凡未脫離本發明技藝精神所為之等效實 施或變更,均應包含於本案之專利範圍中。 ’’r、上所4 ’本案顺1供之-種可降低血獅、抗冑級及抗糖尿病之 醫藥_物確屬_ ’並驗胃舰謂社衫翻效,應已充分符合 新顆性及進步性之法定發明專利要件,爰依法提出申請,懇請貴局核准 本件發明專利申請案,以勵發明,至感德便。 【圖式簡單說明】 ®—為域餵食含有不關量之試驗物質在4、6及8週後對葡萄糖耐 性之影響:_ 4週__試驗組之雜觀結果;卿6週控制組與 〇 試驗組之耐糖試驗結果;(〇第8週控制組與試驗組之耐糖試驗結果。” 圖二為大鼠餵食含有不關量之試驗物質在4、6及8週後對血糖上升 曲線下面積表示圖。 【主要元件符號說明】無 32: All data are expressed by Mean Shi SE (n=4) b : It is a good repair of high-fat feed. Based on the L5 g test substance for the intake of dry weight per adult, the product accounts for (1·5/500) χ 100/〇 = 0.3% of the daily food intake. Therefore, this test is to add the test group feed 〇 3% of the test substance 0 2.2 test substance on serum lipids: The test results in Table 11 show that after the 6-week feeding period, the test group of serum triacid The concentration of glycerol (TG) was 146.7 ± 6.4 mg/dL 'Compared with the serum triglyceride (TG) concentration of the control group of 158.7 ± 16·2 mg/dL, 'in absolute value decreased by 7.6%, but statistically There was no significant difference (p>〇_〇5). 29 200927158 Table 11 hamsters foraging test substances after 6 weeks, the effect on serum biochemical values Animal number I II ΙΠ IV Mean ± SD rate of change (%) b TG (mg / dL) c -- ^ . 丨 ~ control group 134.4 167.4 165.8 167.2 158.7 i 16 2 Test group 141.5 154.5 141.3 149.4 146.7±6 4 -7.6 TC (mg/dL) 1——— Control group 317.3 371.2 306.8 319.2 328.6 i 28.9 Test □ 299.0 310.6 298.1 334.6 310.3 i 17 〇- 5.5 LDL-C (mg/dL) —1 — Control group 133.6 143.6 121.5 136.1 133.7 ±9.2 Test group 125.5 112.5 121.0 125.7 121·2±26Π -9.4 HDL-C (mg/dL) —- Control group 131.8 68.2 102.3 162.8 116.3 ±40.5 Test group 114.7 82.2 82.2 51.26 -29.0 LDL-C/HDL-C ----- Control group 1.0 2.1 1.2 0.8 1.3 : b〇.6 Test group 1.1 1.4 1.5 2.5 1-6 ina +23.1 500 g calculation The recommended daily intake of 1.5 g of test substance per person as the standard food, J intake frequency W) X dirty = 0.3%. The test is called the test group b: rate of change = (control group - test group) / control group X 100%. ❹ ❹ C month cholestyramine; TC: total biliary sputum; LDL_C: Jianlin egg _; HDLC: high density from the test results of Table 10 - shows the serum total cholesterol of the test group after 6 weeks of feeding period ( TC) concentration S 310.6 ± 17. 〇 mg / dL, and control, group Jinqing total cholesterol (TC) concentration of 328.6 ± 28.9 mg / dL after the ratio 'has a 5.5% decline, but statistically No significant difference ^ > 30 200927158 0.05). From the test data in Table 11, the serum low density lipoprotein cholesterol (LDL-C) of the test group was 121.2 ± 6.2 mg/dL ' compared with 133.7 soil 9·2 mg/dL of the control group, although there was a 9.4% decrease. The situation was statistically not significantly different (p >〇.〇5); serum high-density lipoprotein cholesterol (HDL-C) concentrations were 82.6 ± 26.0 and 116.3 ± 40.5 mg in the test and control groups, respectively. /dL 'The results show no significant difference 7> 0 05). The LDL-C/HDL-C ratios for the atherosclerotic risk factors were further calculated in the control group and the experimental group, which were 1.3 ± 0.6 and 1.6 soil 0.6, respectively, but there was no statistically significant difference b > 0.05) 〇 3 Summary: The results of this test showed that hamsters ingested 0.3% of the test substance (ie, the dipper leaf extract obtained in the example) for a period of 6 weeks, which slightly reduced serum triglyceride (TG). The total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) decreased by 7.6, 5_5, and 9.4%, respectively, but there was no significant difference in the increase of serum high-density lipoprotein cholesterol; therefore, in this test The burr leaf extract under conditions has the ability to partially regulate lipids in the blood. The invention provides a pharmaceutical composition for reducing blood fat, anti-hyperuric acid and anti-diabetes, which has the following advantages when compared with the conventional formula: 1. The invention provides the blood fat reduction and anti-reduction The high-uric acid and anti-diabetic pharmaceutical composition is made of rags, so it does not have the destructive influence of roots and bark-like wood growth, and the material is fresher than the roots and bark, which can save labor. Therefore, the cost of materials can be greatly reduced. 31 200927158 2. The invention provides a pharmaceutical composition for lowering blood fat, anti-hyperuric acid and anti-diabetes, which has the effect of partially regulating grees, uric acid and blood sugar without the need of other prescriptions. It has the potential to develop scientific towel medicines for antihypertensive, high uric acid and diabetes. - i 顺 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ It should be included in the patent scope of this case. ''r, Shangshang 4' This case is for the sake of 1 - can reduce the blood lion, anti-caries and anti-diabetes medicine _ things are indeed _ 'and the stomach ship said that the body sweater effect, should have fully met the new Sexual and progressive statutory invention patent requirements, 提出 apply in accordance with the law, and ask your bureau to approve the invention patent application, in order to invent invention, to the sense of virtue. [Simple description of the diagram] ® - The effect of the test substance containing the uncontrolled substance on the glucose tolerance after 4, 6 and 8 weeks: _ 4 weeks __ the results of the test group; the 6-week control group The results of the sugar tolerance test of the sputum test group; (the results of the sugar tolerance test of the control group and the test group at the 8th week.) Figure 2 shows the rats under the control of the blood glucose rise curve after 4, 6 and 8 weeks. Area representation. [Main component symbol description] No 32
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW96148437A TW200927158A (en) | 2007-12-18 | 2007-12-18 | A medicament composition capable of lowering blood lipid, anti-high uric acid, and anti-diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW96148437A TW200927158A (en) | 2007-12-18 | 2007-12-18 | A medicament composition capable of lowering blood lipid, anti-high uric acid, and anti-diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200927158A true TW200927158A (en) | 2009-07-01 |
Family
ID=44863483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW96148437A TW200927158A (en) | 2007-12-18 | 2007-12-18 | A medicament composition capable of lowering blood lipid, anti-high uric acid, and anti-diabetes |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TW200927158A (en) |
-
2007
- 2007-12-18 TW TW96148437A patent/TW200927158A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Syed | Nutritional and therapeutic importance of the pumpkin seeds | |
| Pan et al. | Meta-analysis of the effects of flaxseed interventions on blood lipids | |
| Jyothirmayi et al. | Banana medicinal uses | |
| CN103520179B (en) | Hyperlipidemia improving agent, anemia improve compositions, uric acid level reduces compositions and beverage/food | |
| JP2008174539A (en) | Healthy and functional food for obesity patient using purple-colored potato | |
| Atefi et al. | Meta-analysis of the effects of quinoa (Chenopodium quinoa) interventions on blood lipids | |
| Arooj et al. | A comprehensive review of the bioactive components of sesame seeds and their impact on bone health issues in postmenopausal women | |
| AU2008332981B2 (en) | Use of phytoecdysones in the preparation of a composition for acting on metabolic syndrome | |
| Gupta et al. | Effect of germinated Glycine max seeds on glycemic control in STZ+ NAD induced type 2 diabetic models: a preliminary study. | |
| Venugopal et al. | Management of diabetic dyslipidemia with subatmospheric dehydrated barley grass powder | |
| Egwumah et al. | Managing hypertension: the role of a food scientist and nutritionist | |
| KR101369060B1 (en) | Antiobesity composition containing component originating in the bark of tree belonging to the genus acacia | |
| TW200927158A (en) | A medicament composition capable of lowering blood lipid, anti-high uric acid, and anti-diabetes | |
| Park et al. | Effect of an extract of Pinus koraiensis leaves, Lycium chinense fruit, and Saururus chinensis (lour.) Baill. Leaves on liver function in excessive drinkers: A randomized, double-blind, placebo-controlled trial | |
| Agab et al. | The Impact of Aqueous Piliostigma thonningii Fruit Extract on Certain Biochemical Parameters on Male Wister Albino Rats | |
| US8241682B2 (en) | Effects of Dichrostachys glomerata DG, Hypodaphnis zenkeri HZ, and Xylopia aethiopica XA on various cardiovascular risk factors and metabolic syndrome | |
| Button et al. | Phytoestrogens for osteoporosis | |
| Ayo-Lawal et al. | Antihyperlipidaemic and antioxidant potential of fermented Citrullus vulgaris seeds (Thunb.) on tyloxapol-induced hyperlipidaemic rats: a comparison with fluvastatin | |
| Nwankwo et al. | Sphenostylis stenocarpa: An Under-utilized Legume with Nutraceutical Potentials-A Review. | |
| Kaabi | Evaluation of the aqueous extract of Musa acuminata Corm (Rhizome) for its anti-diabetic potential in streptozotocin (STZ) induced diabetic zebrafish (Danio rerio) model | |
| Singh et al. | Generic information on fennel to combat cough and cold in COVID19 era | |
| Tedi | Study Literature: Acacia Plants Lower Blood Sugar | |
| Yonei et al. | Anti-glycation and improvement microbiota by Geranium dielsianum extract: Relation to health problems in athletes. | |
| McAlpine | Tea types and their effects on in vitro mineralization and in vivo bone structure and density | |
| Majeed et al. | A new class of phytonutrients for body weight management |